Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults

Current Medical Research and Opinion

Volumn 20, Issue 2, 2004, Pages 131-137

  Bronsky, Edwin A ^a   Grossman, Jay ^b   Henis, Marc J ^c   Gallo, Paul P ^c   Yegen, Ümit ^c   Della Cioppa, Giovanni ^d   Kottakis, John ^d   Mehra, Sunil ^c  

^a UNIVERSITY OF UTAH   (United States)

^b Allergy Care Consultants Ltd   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Aerolizer; Asthma; Breath actuated inhaler; Forced inspiratory vital capacity; Peak inspiratory flow rate

Indexed keywords

FORMOTEROL FUMARATE;

ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; ASTHMA; BREATHING; CHILD; COMPARATIVE STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRY POWDER; FEMALE; FORCED INSPIRATORY VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; PEAK INSPIRATORY FLOW RATE; POWDER INHALER; RESPIRATORY AIRFLOW; SIDE EFFECT; SPIROMETRY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CONSUMER PRODUCT SAFETY; ETHANOLAMINES; FEMALE; HUMANS; INHALATION; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 1042291228     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002793     Document Type: Article

References (35)

1. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 2003;16:79-95
2. Montreal Protocol. Montreal protocol on substances that deplete the ozone layer. ILM 1987;16:1541
3. Smith IJ. The challenge of reformulation. J Aerosol Med 1995;8(Suppl 1):S19-27
4. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94(Suppl B):S3-9
5. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999;12(Suppl 1):S9-17
6. Roche N, Huchon GJ. Rationale for the choice of an aerosol delivery system. J Aerosol Med 2000;13:393-404
7. National Asthma Education and Prevention Program. 1998. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: US Dept of Health and Human Services, Public Health Service. NIH publication No. 98-4051
8. Clark AR. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. Respir Drug Deliv 1994;4L:117-23
9. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993;6:99-110
10. McKenzie DK, Gandevia SC. Strength and endurance of inspiratory, expiratory, and limb muscles in asthma. Am Rev Respir Dis 1986;134:999-1004
11. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001;120:89-93S
12. Saccar CL. Comparative evaluation of therapeutic response to antiasthma drugs: dry powder vs. conventional aerosol delivery systems. J Aerosol Med 1996;9:89-94
13. Liard R, Zureik M, Aubier M, Korobaeff M, Henry C, Neukirch F. Misuse of pressurized metered dose inhalers by asthmatic patients treated in French private practice. Rev Epidemiol Sante Publique 1995;43:242-9
14. Clauzel AM, Molimard M, Le Gros V, Lepère E, Febvre N, Michel FB. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients. Invest Allergol Clin Immunol 1998;8:265-70
15. Thomson NC, Angus R, Quebe-Fehling E, Brambilla R. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998;92:562-7
16. Häcki MA, Hinz GW, Medici TC. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest 1997;14:165-74
17. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725-34
18. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293-304
19. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur Respir J 1997;10:2105-9
20. Clark AR, Bailey R. Inspiratory flow profiles in disease and their effects on the delivery characteristics of dry powder inhalers. Respir Drug Deliv 1996;5:221-30
21. Nantel NP, Newhouse MT. Inspiratory flow rates through a novel dry powder inhaler (Clickhaler) in pediatric patients with asthma. J Aerosol Med 1999;12:55-8
22. Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler®). Eur Respir J 1990;3:1037-41
23. Brown PH, Ning ACWS, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through the Turbuhaler® in acute asthma. Eur Respir J 1995;8:1940-1
24. van der Mark TW, Meijer MR, Posa DS, Koëter GH. Reliable peak inspiratory flow through Turbuhaler in asthmatic patients [abstract]. Am J Respir Crit Care Med 1994;149:A193
25. Spiro SJ, Biddiscombe M, Marriott RJ, Short M, Taylor AJ. Inspiratory flow rates attained by asthmatic patients through a metered-dose inhaler and a Diskhaler® inhaler. Br J Clin Res 1992;3:115-16
26. Cherniack RM. Physiologic diagnosis and function in asthma. Clin Chest Med 1995;16:567-81
27. Perez T, Becquart LA, Stach B, Wallaert B, Tonnel AB. Inspiratory muscle strength and endurance in steroid-dependent asthma. Am J Respir Crit Care Med 1996;103:610-15
28. Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease: a 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995;50:657-63
29. FitzGerald JM, Chapman KR, Della Cioppa G, et al., Canadian FO/OD1 Study Group. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999;103:427-35
30. Vervloet D, Ekström T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998;92:836-42
31. Ifversen M, Bisgaard H, Klug B, Skamstrup K, Sumby B. Inspiratory flow rate through the Diskus/Accuhaler inhaler and Turbuhaler inhaler in children with asthma [abstract]. Eur Respir J 1995;8:428S
32. Chew NY, Chan HK. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001;14:495-501
33. Meakin BJ, Dimond PD. Bricanyl Turbohaler, Serevent Accuhaler & Foradil® Aerolizer: comparative drug delivery [abstract]. Thorax 1996;51 (Suppl 3):A73
34. Chew NYK, Chan HK. In vitro performance of Foradil® Aerolizer™ and Oxis® Turbuhaler®. Respir Drug Deliv 2000;7:623-4
35. Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res 1995;7:177-93